Disclosed positions
| NUVALENT INC | NUVL | COM | $2,130,183,575 | 17,248,450 | SH | None |
| BROOKDALE SR LIVING INC | Unresolved | NOTE 3.500%10/1 | $585,704,753 | 306,885,000 | PRN | None |
| REVOLUTION MEDICINES INC | RVMD | COM | $447,973,760 | 2,392,000 | SH | None |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $322,520,281 | 963,351 | SH | None |
| VIATRIS INC | VTRS | COM | $320,873,980 | 20,206,170 | SH | None |
| CENTENE CORP DEL | CNC | COM | $314,595,190 | 4,901,000 | SH | None |
| REVOLUTION MEDICINES INC | Unresolved | NOTE 0.500% 5/0 | $251,681,000 | 200,000,000 | PRN | None |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $247,616,310 | 457,000 | SH | None |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | NOTE 1/1 | $240,537,600 | 200,000,000 | PRN | None |
| LEGEND BIOTECH CORP | LEGN | SPONSORED ADS | $235,014,985 | 8,137,638 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $193,736,225 | 5,006,104 | SH | None |
| GENMAB A/S | GMAB | SPONSORED ADS | $188,581,550 | 6,865,000 | SH | None |
| BROOKDALE SR LIVING INC | BKD | COM | $187,239,845 | 11,637,032 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $168,052,724 | 3,916,400 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $156,967,955 | 1,979,669 | SH | None |
| CELCUITY INC | CELC | COM | $151,805,085 | 1,451,014 | SH | None |
| BIOCRYST PHARMACEUTICALS INC | BCRX | COM | $150,964,030 | 15,096,403 | SH | None |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $144,533,699 | 4,264,789 | SH | None |
| ACADIA HEALTHCARE COMPANY IN | ACHC | COM | $133,475,600 | 4,520,000 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $130,998,500 | 4,190,611 | SH | None |
| ADAPTHEALTH CORP | AHCO | COMMON STOCK | $119,597,947 | 11,477,730 | SH | None |
| PHARVARIS N V | PHVS | COM | $116,743,532 | 3,376,042 | SH | None |
| CELCUITY INC | Unresolved | NOTE 0.250% 8/0 | $113,779,900 | 100,000,000 | PRN | None |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | COM | $113,221,873 | 1,389,055 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $109,695,511 | 1,125,313 | SH | None |
| LARIMAR THERAPEUTICS INC | LRMR | COM | $108,601,271 | 35,606,974 | SH | None |
| MINERALYS THERAPEUTICS INC | MLYS | COM | $106,786,840 | 3,958,000 | SH | None |
| ALIGNMENT HEALTHCARE INC | ALHC | NOTE 4.250%11/1 | $103,829,930 | 61,000,000 | PRN | None |
| IDEAYA BIOSCIENCES INC | IDYA | COM | $101,169,527 | 2,714,503 | SH | None |
| XENON PHARMACEUTICALS INC | XENE | COM | $97,523,411 | 1,615,696 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | NOTE 1.750% 6/1 | $93,104,400 | 60,000,000 | PRN | None |
| SAVARA INC | SVRA | COM | $83,585,040 | 13,569,000 | SH | None |
| LANTHEUS HLDGS INC | LNTH | COM | $83,537,709 | 752,999 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $82,628,614 | 3,779,900 | SH | None |
| ZENAS BIOPHARMA INC | Unresolved | NOTE 2.500% 4/0 | $80,316,096 | 67,200,000 | PRN | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $76,264,876 | 1,332,836 | SH | None |
| PFIZER INC | PFE | COM | $73,203,200 | 3,040,000 | SH | None |
| INDIVIOR PHARMACEUTICALS INC | INDV | COM | $67,654,162 | 1,648,895 | SH | None |
| BIO RAD LABS INC | BIO | CL A | $66,376,413 | 226,070 | SH | None |
| ARS PHARMACEUTICALS INC | SPRY | COM | $60,105,534 | 7,503,812 | SH | None |
| STOKE THERAPEUTICS INC | STOK | COM | $59,664,920 | 1,823,500 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $58,285,620 | 1,086,000 | SH | None |
| ENVISTA HOLDINGS CORPORATION | NVST | COM | $58,236,135 | 2,210,100 | SH | None |
| INSPIRE MED SYS INC | INSP | COM | $57,853,014 | 1,296,862 | SH | None |
| CAREDX INC | CDNA | COM | $56,932,113 | 1,997,618 | SH | None |
| BOSTON SCIENTIFIC CORP | BSX | COM | $56,124,200 | 1,315,000 | SH | None |
| BELITE BIO INC | BLTE | SPONSORED ADS | $55,003,288 | 357,199 | SH | None |
| PARABILIS MEDICINES INC | PBLS | COM | $51,474,868 | 1,880,704 | SH | None |
| CERTARA INC | CERT | COM | $49,209,678 | 7,512,928 | SH | None |
| DISC MEDICINE INC | IRON | COM | $48,052,980 | 657,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 8 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.